title: Recombinant soluble human thrombomodulin: a randomized, blinded assessment of prevention of venous thrombosis and effects on hemostatic parameters in a rat model.
abstract: Thrombomodulin is an endothelial surface receptor that binds thrombin and accelerates the activation of protein C. We compared the effects of a recombinant thrombomodulin analog (TME), recombinant hirudin (r-HIR), heparin sodium (HEP), and normal saline (Control) on thrombus formation, activated partial thromboplastin time (APTT), thrombin time (TT), platelet aggregation and tail transection bleeding time (BT) in a rat model of vena cava thrombosis.
  
  
  RESULTS
  TME, r-HIR and HEP prevented venous thrombosis in this model in a dose-dependent manner. At the dose required to reduce vena cava thrombosis by 50% (ED50), TME did not prolong the APTT or TT as did HEP and r-HIR. Platelet aggregation in response to thrombin was not effected by TME but was inhibited by both r-HIR and HEP. BT did not differentiate the agents tested.
  
  
  CONCLUSIONS
  TME inhibited venous thrombosis in a rat vena cava model with less effect on hemostatic variables than HEP or r-HIR.
authors.affiliation: Department of Surgery, University of Arkansas for Medical Sciences, Little Rock.
authors.forename: M M
authors.initials: MM
authors.lastname: Solis
authors.forename: M
authors.initials: M
authors.lastname: Vitti
authors.forename: J
authors.initials: J
authors.lastname: Cook
authors.forename: D
authors.initials: D
authors.lastname: Young
authors.forename: C
authors.initials: C
authors.lastname: Glaser
authors.forename: D
authors.initials: D
authors.lastname: Light
authors.forename: J
authors.initials: J
authors.lastname: Morser
authors.forename: R
authors.initials: R
authors.lastname: Wydro
authors.forename: S
authors.initials: S
authors.lastname: Yu
authors.forename: L
authors.initials: L
authors.lastname: Fink
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects*; D006493:Heparin / Q000627:therapeutic use; D024764:Hirudin Therapy; D006801:Humans; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000627:therapeutic use; D012995:Solubility; D018180:Thrombomodulin; D013927:Thrombosis / Q000517:prevention & control*; D014682:Vena Cava, Inferior
chemical_list: D011994:Recombinant Proteins; D018180:Thrombomodulin; D006493:Heparin